Hypertension management 2011: Optimal combination therapy

European Heart Journal

Volumn 32, Issue 20, 2011, Pages 2499-2506

  Sever, Peter S ^a   Messerli, Franz H ^b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

Combination therapy; Hypertension

Indexed keywords

ALISKIREN; ALPHA 1 ADRENERGIC RECEPTOR BLOCKING AGENT; AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; ATENOLOL; BENAZEPRIL; BENDROFLUMETHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; GUANETHIDINE; HYDRALAZINE; HYDROCHLOROTHIAZIDE; LISINOPRIL; LOSARTAN; METHYLDOPA; NIFEDIPINE; PENTOLONIUM TARTRATE; PERINDOPRIL; PLACEBO; PRAZOSIN; PROPRANOLOL; RENIN INHIBITOR; UNINDEXED DRUG; VALSARTAN; VERAPAMIL;

ANTIHYPERTENSIVE ACTIVITY; ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DOSE RESPONSE; DRUG EFFICACY; DRUG MECHANISM; EDEMA; ENVIRONMENTAL FACTOR; FLUID RETENTION; FOOT EDEMA; HEREDITY; HUMAN; HYPERTENSION; MONOTHERAPY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REFLEX; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK REDUCTION; SIDE EFFECT; STROKE; SYMPATHETIC BLOCKING; SYSTOLIC BLOOD PRESSURE; TACHYCARDIA; TREATMENT OUTCOME; TREATMENT RESPONSE; VASCULAR RESISTANCE; VASODILATATION;

ADRENERGIC BETA-ANTAGONISTS; ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; CALCIUM CHANNEL BLOCKERS; DIURETICS; DRUG THERAPY, COMBINATION; HUMANS; HYPERTENSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 80054726950     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehr177     Document Type: Review

References (54)

1. Page IH. The MOSAIC theory. In Page IH, ed. Hypertension Mechanisms. New York: Grune and Stratton, 1987 p910-923.
2. Sever PS. The heterogeneity of hypertension: why doesn't every patient respond to every antihypertensive drug? J Hum Hypertens 1995;9:S33-S36.
3. Mimran A, Ribstein J, Du Cailar G. Converting enzyme inhibitors and renal function in essential and renovascular hypertension. Am J Hypertens 1991;4(Suppl. 1): 7S-14S.
4. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ. Optimisation of antihypertensive treatment by cross-over rotation of four major classes. Lancet 1999;353:2008-2013. (Pubitemid 29271745)
5. Matterson BJ, Reda DJ, Cushman WC. Department of Veterans Affairs. Single-therapy of hypertension study. Revised figures and new data. Department of Veterans' Affairs Cooperative Study Group on Antihypertensive Agents. Am J Hypertens 1995;8:189-192.
6. Law MR, Wald NJ, Morris JK, Jordan RE. Value of low dose combination treatment with blood pressure lowering drugs: Analysis of 354 randomised trials. BMJ 2003;326:1427-1435.
7. Attwood S, Bird R, Burch K, Casadei B, Coats A, Conway J, Dawes M, Ebbs D, Farmer A, Robinson J, Sherlock C. Within-patient correlation between the antihypertensive effects of atenolol, lisinopril and nifedepin. J Hypertens 1994;12: 1053-1060. (Pubitemid 24294817)
8. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: Meta-analysis on 11,000 participants from 42 trials. Am J Med 2009;122:290-300.
9. Jamerson KA. Rationale for angiotensin II receptor blockers in patients with lowrenin hypertension. Am J Kidney Dis 2000;36(Suppl. 1):S24-S30.
10. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, Jones DW, Materson BJ, Oparil S, Wright JT Jr,, Roccella EJ; Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. National Heart, Lung, and Blood Institute; National High Blood Pressure Education Program Coordinating Committee. Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206-1252.
11. MacMahon S. Blood pressure and the risks of cardiovascular disease. In Swales JD, ed. Textbook of Hypertension. Blackwell Scientific Publication, 1994, p46-57.
12. Mancia G, De Backer G, Dominiczak A, Cifkova R, Fagard R, Germano G, Grassi G, Heagerty AM, Kjeldsen SE, Laurent S, Narkiewicz K, Ruilope L, Rynkiewicz A, Schmieder RE, Struijker Boudier HA, Zanchetti A; European Society of Hypertension; European Society of Cardiology. 2007 ESH-ESC Guidelines for the management of arterial hypertension: The task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007;16:135-232.
13. Mancia G, Laurent S, Agabiti-Rosei E, Ambrosioni E, Burnier M, Caulfied MJ, Cifkova R, Clement D, Coca A, Dominiczak A, Erdine S, Fagard R, Farsang C, Grassi G, Haller H, Heagerty A, Kjeldsen SE, Kiowski W, Mallion JM, Manolis A, Narkiewicz K, Nilsson P, Olsen MH, Rahn KH, Redon J, Rodicio J, Ruilope L, Schmieder RE, Struijker-Boudier HA, Van Zwieten PA, Viigimaa M, Zanchetti A. Reappraisal of European guidelines on hypertension managements: A European Society of Hypertension Task Force document. J Hum Hypertens 2009;27:2121-2158.
14. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, Thom SM; BHS guidelines working party for the British Hypertension Society. Guidelines for the management of hypertension: Report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004;18:139-185. (Pubitemid 38425770)
15. Messerli FH, Mancia G, Conti CR, Hewkin AC, Kupfer S, Champion A, Kolloch R, Benetos A, Pepine CJ. Dogma disputed: Can aggressively lowering blood pressure in hypertensive patients with coronary artery disease be dangerous? Ann Intern Med 2006;144:884-893. (Pubitemid 46768128)
16. Bangalore S, Messerli FH, Wun C, Zuckerman AL, DeMicco D, Kostis JB, La Rosa JC. Treating to New Targets Steering Committee and Investigators. J-Curve revisited: An analysis of the Treating to New Targets (TNT) Trial. Am J Coll Cardiol 2009;53:A219.
17. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Programme (SHEP). JAMA 1991;265:3255-3264.
18. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Dahlöf B, Sever PS, Poulter NR. Prognostic significance of visit-to-visit variability, maximum systolic blood pressure, and episodic hypertension. Lancet 2010;375:895-905.
19. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive- drug class on interindividual variation in blood pressure and risk of stroke: A systematic review and meta-analysis. Lancet 2010;375:906-915.
20. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs; results of prospectively designed overviews of randomised trials. Lancet 2000;356: 1955-1964.
21. Blood Pressure Lowering Treatment Trialists' Collaboration. Effects of different blood-pressure-lowering regimens on major cardiovascular events: Results of prospectively-designed overviews of randomised trials. Lancet 2003;362: 1527-1535.
22. Nice guidelines. Management of hypertension in adults in primary care. 2004. www.nice.org.uk.
23. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002;359:995-1003. (Pubitemid 34286536)
24. Dahlöf B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; for the ASCOT Investigators. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): A multicentre randomised controlled trial. Lancet 2005;366: 895-906. (Pubitemid 41265663)
25. Jamerson K, Weber MA, Bakris GL, Dahlöf B, Pitt B, Shi V, Hester A, Gupte J, Gatlin M, Velazquez EJ; ACCOMPLISH Trial Investigators. Benazepril plus amlodipine or hydrochlorothiazide for hypertension in high-risk patients. NEJM 2008;359:2417-2428.
26. Julius S, Kjeldsen SE, Brunner H, Hansson L, Platt F, Ekman S, Laragh JH, McInnes G, Schork AM, Smith B, Weber M, Zanchetti A; VALUE Trial. VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk. Am J Hypertens 2003;7:544-548. (Pubitemid 36829703)
27. Poulter NR, Wedel H, Dahlöf B, Sever PS, Beevers DG, Caulfield M, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J, Pocock S; for the ASCOT Investigators. Role of blood pressure and other variables in the differential cardiovascular event rates noted in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA). Lancet 2005;366:907-913. (Pubitemid 41265664)
28. Williams B, Lacy PS, Thom SM, Cruickshank K, Stanton A, Collier D, Hughes AD, Thurston H, O'Rourke M; CAFE Investigators; Anglo-Scandinavian Cardiac Outcomes Trial Investigators; CAFE Steering Committee and Writing Committee. Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: Principal results of the Conduit Artery Function Evaluation (CAFE) study. Circulation 2006;113:1213-1225.
29. Rothwell PM, Howard SC, Dolan E, O'Brien E, Dobson JE, Poulter NR, Sever PS; on behalf of the ASCOT-BPLA and MRC Trial Investigators. Effects of b-blockers and calcium-channel blockers on within-individual variability in blood pressure and risk of stroke. Lancet Neurol 2010;9:469-480.
30. Weber MA, Bakris GL, Jamerson K, Weir M, Kjeldsen SE, Devereux RB, Velazquez EJ, Dahlof B, Kelly RY, Hua TA, Hester A, Pitt B; for the ACCOMPLISH Investigators. Cardiovascular events during differing hypertension therapies in patients with diabetes. JACC 2010;56:77-85.
31. Makani H, Bangalore S, Romero J, Wever-Pinzon O, Messerli FH. Effect of renin-angiotensin-system blockade on calcium channel blockers associated peripheral edema. Am J Med 2011;124:128-135.
32. Sever PS, Poulter NR. Management of hypertension: Is it the pressure or the drug? Blood pressure reduction is not the only determinant of outcome. Circulation 2006;113:2754-2774.
33. Pepine CJ, Handberg EM, Cooper-DeHoff RM, Marks RG, Kowey P, Messerli F, Mancia G, Cangiano JL, Garcia-Barreto D, Keltai M, Erdine S, Bristol HA, Kolb HR, Bakris GL, Cohen JD, Parmley WW; INVEST Investigators. A calcium antagonist vs. a non-calcium antagonist hypertension treatment strategy for patients with coronary artery disease. The International Verapamil-Trandolapril Study (INVEST): A randomised controlled trial. JAMA 2003;290:2805-2819.
34. Beckett NS, Peters R, Fletcher AE, Staessen JA, Liu L, Dumitrascu D, Stoyanovsky V, Antikainen RL, Nikitin Y, Anderson C, Belhani A, Forette F, Rajkumar C, Thijs L, BanyaW, Bulpitt CJ, for the HYVET Study Group. Treatment of hypertension in patients 80 years of age and older. NEJM 2008;358: 1887-1898. (Pubitemid 351620109)
35. Alviar CL, Devarapally S, Romero J, Benjo AM, Nadkarni G, Javed F, Suryadevara R, Kang H, Messerli FH. Efficacy and Safety of Dual Calcium Channel Blocker Therapy for the Treatment of Hypertension: A Meta-analysis. ASH, 2010.
36. Messerli FH, Staessen JA, Zannad F. Of fads, fashion, surrogate endpoints and dual RAS blockade. Eur Heart J 2010; Aug 3. [Epub ahead of print].
37. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, Dagenais G, Sleight P, Anderson C; the ON-TARGET Investigators. Telmisartan, ramipril, or both in patients at high risk for vascular events. NEJM 2008;358:1547-1559. (Pubitemid 351522739)
38. Oparil S, Yarrows SA, Patel S, Zhang J, Satlin A. Dual inhibition of the renin system by aliskiren and valsartan. Lancet 2007;370:1126-1127. (Pubitemid 47464577)
39. Alvarez-Alvarez B. Management of resistant arterial hypertension: Role of spironolactone versus double blockade of the renin-angiotensin-aldosterone system. J Hypertens 2010; Jul 21. [Epub ahead of print].
40. Bailey RR, Neale TJ. Rapid clonidine withdrawal with blood pressure overshoot exaggerated by beta-blockade. BMJ 1976;6015:942-943.
41. Chapman N, Chang CL, Dahlof B, Sever PS, Wedel H, Poulter NR, for the ASCOT Investigators. Effect of doxazosin gastrointestinal therapeutic system as third-line antihypertensive therapy on blood pressure and lipids in the Anglo-Scandinavian Cardiac Outcomes Trial. Circulation 2008;118:42-48.
42. ALLHAT Officers and Coordinators for the ALLHATT Collaborative Research Group. Diuretic versus a-blocker as first-step antihypertensive therapy. Final results from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Hypertension 2003;42:239-246.
43. Chapman N, Dobson J, Wilson S, Dahlof B, Sever PS, Wedel H, Poulter NR, on behalf of the ASCOT Trial Investigators. Effect of spironolactone on blood pressure in subjects with resistant hypertension. Hypertension 2007;49:839-845. (Pubitemid 351664214)
44. Lv Y, Zou Z, Chen GM, Jia HX, Zhong J, Fang WW. Amlodipine and angiotensinconverting enzyme inhibitor combination versus amlodipine monotherapy in hypertension: A meta-analysis of randomised control trials. Blood Press Monit 2010;15:195-204.
45. Messerli FH, Grossman E. Pedal edema-not all dihydropyridine calcium antagonists are created equal. Am J Hypertens 2002;15:1019-1020. (Pubitemid 35217412)
46. Kaplan N. Clinical Hypertension. In Kaplan NM, ed. 8th ed. Lippincott Williams and Wilkins, 2002, p247.
47. Hypertension Detection and Follow-up Programme Cooperative Group (HDFP). Five-year findings of the Hypertension Detection and Follow-Up programme: Reduction in mortality in persons with high blood pressure, including mild hypertension. JAMA 1979;242:2562-2571.
48. Lindholm LH, Carlberg B, Samuelssson O. Should b blockers remain first choice in the treatment of primary hypertension? A meta-analysis. Lancet 2005;366: 1545-1553. (Pubitemid 41540112)
49. Gupta AK, Arshad S, Poulter NR. Compliance, safety and effectiveness of fixeddose combinations of antihypertensive agents: A meta-analysis. Hypertension 2010; 55:399-407.
50. Bangalore S, Kamalakkannan G, Parkar S, Messerli FH. Fixed-dose combinations improve medication compliance: A meta-analysis. Am J Med 2007;120:713-719. (Pubitemid 47176510)
51. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter NR, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004;43:10-17. (Pubitemid 38031904)
52. Redon J, Coca A, Lazaro P, Dolores Aguila M, Cabanas M, Gil N, Sanchez-Zamarano MA, Arand P. Factors associated with therapeutic inertia in hypertension: Validation of a predictive model. J Hypertens 2010;28:1770-1777.
53. Sever PS. Is systolic blood pressure all that matters? BMJ (Head to Head Debate) 2009;339:138-139.
54. Falaschetti E, Chaudhury M, Mindell J, Poulter NR. Continued improvement in hypertension management in England. Results from the Health Survey for England 2006. Hypertension 2009;53:480-486.